Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Bruker; QuantRx; Avesthagen; Cold Spring Harbor Laboratory; BlackBio

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker Energy & Supercon Technologies, a subsidiary of bruker, has filed for an initial public offering in the US. The firm did not say in the prospectus how many shares it intends to offer, and it listed $100 million as the estimated maximum aggregate offering price. Following the offering, parent firm Bruker will continue to hold the majority of shares in BEST, which sells superconducting materials used in applications, such as MRI, NMR, and fusion energy research.

In addition, Bruker said earlier this week that in recognition of its 50th anniversary company officials will ring the opening bell of Nasdaq on Sept. 7.

QuantRx Biomedical said this week that it will relocate its headquarters from Doylestown, Pa., to Portland, Ore., as the firm consolidates its operations. The firm said that the move and consolidation reflects its "transition from the developmental stage to an enterprise focused on the marketing and manufacturing of innovative products for advanced diagnosis of serious disease and health conditions." It also noted that its CFO, Sasha Afanassiev has declined to relocate with the firm.

QuantRx is developing rapid point-of-care diagnostics, and also makes microarrays and molecular imaging agents.

Avesthagen announced today that it has initiated sequencing a set of 60 closely-related human genomes to identify novel genetic information relevant to cancer, metabolic, and neurological disorders as part of its Avestagenome Project. The project is led by the Bangalore, India-based firm and includes research conducted by Genome Enterprise Ltd, a subsidiary of The Genome Analysis Centre in the UK. The project is using Life Technologies' SOLiD 4 sequencing platform with Avesthagen's bioinformatics capabilities to interpret data.

Cold Spring Harbor Laboratory has received a $497,423 grant from the National Science Foundation to renovate and upgrade its plant growth facilities, where it conducts work on Arabidopsis and other crop plants. CSHL said that its current facilities are "inadequate to meet the demands of current genome-driven plant biology research." The funds were awarded under the American Recovery and reinvestment Act of 2009.

Madrid, Spain-based BlackBio this week announced that its BlackLight Sepsis Kit has received the CE Mark. The test is based on pyrosequencing and rapidly identifies bacteria in less than four hours.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.